Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pozelimab and Cemdisiran Combination Therapy in PNH
NCT05744921Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Mar 2023
- Primary completion
- Oct 2028
- Modality
- Antisense DNA, Recombinant Proteins and Enzymes, Conjugated siRNA
- Countries
- 20
01
Overview
Phase 3, open-label trial of pozelimab and cemdisiran in paroxysmal nocturnal hemoglobinuria (PNH) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of treatment-emergent serious adverse events, Severity of treatment-emergent serious adverse events and 5 more. Started Mar 2023; status: recruiting.
02
Drugs
pozelimabcemdisiran
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT05744921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744921.